Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $57.0M | $25.8M | $17.4M | $183M | $451M |
| Revenue growth | — | — | — | — | -54.7% | -32.4% | 948.6% | 146.7% |
| Operating income | — | -$4.30M | -$27.0M | -$12.2M | -$62.7M | -$143M | -$121M | -$71.0M |
| Operating margin | — | — | — | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Net income | -$1.32M | -$4.67M | -$26.8M | -$13.8M | -$62.1M | -$136M | -$116M | -$66.4M |
| Net margin | — | — | — | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| EPS (diluted) | — | -$1.98 | -$4.32 | -$0.67 | -$2.52 | -$4.62 | -$3.07 | -$1.59 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$3.67M | -$21.1M | $3.75M | -$49.0M | -$117M | -$83.0M | -$12.5M |
| Capital expenditures | — | $175K | $456K | $586K | $506K | $1.50M | $1.57M | $9.86M |
| Free cash flow | — | -$3.85M | -$21.6M | $3.16M | -$49.5M | -$119M | -$84.6M | -$22.3M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.38M | $58.0M | $168M | $171M | $71.7M | $225M | $94.8M | $184M |
| Total assets | — | $58.3M | $172M | $179M | $228M | $265M | $377M | $562M |
| Total liabilities | — | $919K | $5.99M | $12.2M | $35.0M | $68.5M | $152M | $219M |
| Long-term debt | — | — | — | $0.00 | $19.4M | $29.8M | $71.8M | $72.4M |
| Shareholders' equity | -$1.35M | -$6.00M | $166M | $167M | $193M | $197M | $225M | $343M |
| Retained earnings | — | -$6.03M | -$32.8M | -$46.7M | -$109M | -$245M | -$360M | -$427M |
| Shares (wtd avg diluted) | — | 2.65M | 6.21M | 20.6M | 24.6M | 29.4M | 37.6M | 41.8M |
Every figure is extracted from Tarsus Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.